Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IINN
IINN logo

IINN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.393
Open
0.393
VWAP
0.38
Vol
634.24K
Mkt Cap
17.18M
Low
0.380
Amount
244.10K
EV/EBITDA(TTM)
--
Total Shares
43.27M
EV
14.02M
EV/OCF(TTM)
--
P/S(TTM)
41.41
Inspira Technologies Oxy B.H.N Ltd, formerly Insense Medical Ltd, incorporated on February 27, 2018, is a specialty medical device company based in Israel. The Company is engaged in the research, development, manufacture, and marketing of respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV). It provides patients with acute respiratory distress syndrome to maintain spontaneous breathing and avoid the various risks associated with the use of MV.
Show More

Events Timeline

(ET)
2026-03-31
08:41:00
New
Inspira Technologies Terminates Sales Agreement with A.G.P.
select
2026-02-25 (ET)
2026-02-25
17:40:00
Inspira Technologies Receives Nasdaq Compliance Notice
select
2026-02-18 (ET)
2026-02-18
08:40:00
Inspira Technologies Deploys ART100 System at New U.S. Medical Center
select
2026-02-12 (ET)
2026-02-12
17:00:00
Inspira Technologies Receives Compliance Notification from Nasdaq
select
2026-02-09 (ET)
2026-02-09
07:20:00
Inspira Technologies Receives Approval from Clalit Medical Equipment Committee
select
2026-02-05 (ET)
2026-02-05
08:20:00
Inspira Technologies Issues 6,785,715 Shares at $0.70 Each
select
2026-02-03 (ET)
2026-02-03
09:30:00
Inspira Technologies Validates HYLA System, Enters $50 Billion Market
select
2026-01-29 (ET)
2026-01-29
08:50:00
Inspira Technologies ART100 System Completes Clinical Evaluation
select
2026-01-21 (ET)
2026-01-21
09:00:00
Inspira Technologies Updates on Purchase Order Progress
select

News

seekingalpha
4.5
14:12 PMseekingalpha
Inspira Technologies Terminates Financing Agreements to Optimize Capital Structure
  • Termination of Financing Agreements: Inspira Technologies announced the termination of its sales agreement with A.G.P./Alliance Global Partners and standby equity purchase agreement with YA II PN Ltd, demonstrating the company's commitment to disciplined capital management.
  • No Outstanding Obligations: The company stated that it has issued formal notices to end both financing arrangements, with neither party having any outstanding obligations or further advances, ensuring financial clarity and stability.
  • Strategic Focus Shift: This termination reflects Inspira's preparation for its next strategic phase, emphasizing a cautious approach to capital operations as it aligns its resources for future growth.
  • Market Reaction: Following this announcement, Inspira Technologies' stock price fell 2.03% in premarket trading to $0.389, indicating market concern regarding the company's adjustments to its financing strategy.
seekingalpha
9.5
03-26seekingalpha
Inspira Technologies Reports Disappointing FY Revenue and Increased Losses
  • Disappointing Financial Performance: Inspira Technologies reported FY 2025 revenue of $0.3 million, missing expectations by $0.19 million, indicating significant pressure in market competition that may affect future financing capabilities.
  • Increased R&D Expenses: For the twelve months ending December 31, 2025, R&D expenses rose to $7.496 million from $6.323 million in 2024, reflecting an 18.5% increase; however, this spending has not effectively translated into revenue, highlighting slow progress in technology development.
  • Widening Net Loss: The net loss for FY 2025 was $13.22 million, a 19.6% increase from the $11.053 million loss in 2024, raising concerns among investors about the company's financial health and potentially impacting stock performance.
  • Tightening Cash Flow: As of December 31, 2025, cash and cash equivalents totaled $3.159 million, down 45.4% from $5.779 million in 2024, indicating reduced liquidity that may constrain the company's operational and growth capabilities.
Newsfilter
9.5
03-26Newsfilter
Inspira Technologies Reports 2025 Financial Results and Strategic Updates
  • Clinical Validation Progress: In April 2025, Inspira successfully treated its first patient using the ART100 system at Westchester Medical Center, marking a critical milestone in validating the system's real-world clinical performance, with subsequent deployments at multiple leading medical centers in the U.S. expanding its clinical application.
  • Initial Commercial Success: In mid-2025, Inspira secured binding purchase orders totaling $49.5 million, representing its first large-scale commercial commitments, with revenue expected to be primarily recognized in 2026, demonstrating the company's initial success in the medical device market.
  • Increased R&D Spending: Research and development expenses reached $7.496 million in 2025, up from $6.323 million in 2024, primarily due to higher share-based compensation and exchange rate fluctuations, reflecting the company's ongoing investment in technology development.
  • Enhanced Liquidity: The company completed a registered direct offering at year-end, raising approximately $4.75 million, strengthening its liquidity to support commercial execution and strategic initiatives in 2026, ensuring compliance with Nasdaq's shareholder equity requirements for continued listing.
Newsfilter
8.5
02-18Newsfilter
Inspira Technologies Deploys ART100 System at Leading U.S. Hospital
  • Market Expansion: Inspira Technologies has deployed its FDA-cleared INSPIRA™ ART100 system at a leading U.S. academic medical center, further expanding its presence in the Tier-1 hospital market, which is expected to enhance the company's market share in the medical device sector.
  • Clinical Evaluation Initiation: The ART100 system has been integrated into the center's clinical workflow to support a structured evaluation aimed at defining clinical protocols and facilitating broader institutional adoption, paving the way for future commercialization.
  • Strategic Execution: Mike Hershkovitz, Global VP Sales, stated that this deployment represents a continued execution of the company's U.S. commercial strategy, demonstrating that the ART100 meets the operational and clinical demands of top-tier healthcare providers, thereby strengthening the company's competitive position in the industry.
  • Future Development Potential: Inspira Technologies is advancing the development of the next-generation INSPIRA ART500 system, designed to provide oxygenation support while patients remain awake, further solidifying its market position within the life-support and MedTech landscape.
Newsfilter
8.5
02-17Newsfilter
Inspira Technologies Showcases FDA-Cleared ART100 System
  • Strategic Showcase: Inspira Technologies will present its FDA-cleared INSPIRA™ ART100 system at the AmSECT International Conference from March 25-29, 2026, in Austin, Texas, aiming to engage clinical decision-makers who influence hospital purchasing decisions and enhance market visibility.
  • Leveraging FDA Approval: The ART100 system, which received FDA 510(k) clearance in May 2024, will be showcased to validate its readiness for clinical integration in cardiopulmonary bypass procedures, thereby accelerating market penetration.
  • Active Distribution Channel: The collaboration with Glo-Med Networks Inc. for the presentation demonstrates Inspira's active commercial pipeline, marking a transition from development to sales execution and market visibility, enhancing its competitive position.
  • Key Phase in Commercial Strategy: Global VP Sales Mike Hershkovitz noted that this event represents a critical phase in the company's U.S. commercial strategy, aimed at expanding clinical partnerships and distribution footprint to drive rapid market share growth.
stocktwits
8.5
02-09stocktwits
Inspira Technologies Secures Major Procurement Approval
  • Stock Surge: Inspira Technologies OXY (IINN) shares surged over 28% in pre-market trading on Monday, reflecting strong market interest and heightened investor confidence in the company's new product.
  • Procurement Approval: Israel's largest health services provider, Clalit Health Services, approved the procurement of Inspira's FDA-cleared ART100 platform, marking a significant milestone in the medical device sector for the company.
  • Market Reach: The ART100 system will be rapidly deployed across Clalit’s healthcare network, which serves approximately 4.9 million members, indicating a swift expansion of the company's market share and enhanced brand presence.
  • Clinical Validation: The approval of ART100 represents not only a successful regulatory clearance but also strong clinical validation for its application in cardiopulmonary bypass and ECMO procedures, signaling substantial future commercial growth potential.

Valuation Metrics

The current forward P/E ratio for Inspira Technologies Oxy BHN Ltd (IINN.O) is -5.94, compared to its 5-year average forward P/E of -2.28. For a more detailed relative valuation and DCF analysis to assess Inspira Technologies Oxy BHN Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.28
Current PE
-5.94
Overvalued PE
-0.61
Undervalued PE
-3.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.05
Current EV/EBITDA
-18.10
Overvalued EV/EBITDA
2.47
Undervalued EV/EBITDA
-6.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.21
Current PS
1.33
Overvalued PS
38.12
Undervalued PS
-17.70

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks under $1 with an rsi under 20
Intellectia · 53 candidates
Price: <= $1.00Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
AIIO logo
AIIO
Robo.ai Inc
89.22M
PSTV logo
PSTV
Plus Therapeutics Inc
52.05M
HURA logo
HURA
TuHURA Biosciences Inc
41.71M
XLO logo
XLO
Xilio Therapeutics Inc
40.33M
POM logo
POM
PomDoctor Ltd
35.21M
OTLK logo
OTLK
Outlook Therapeutics Inc
32.44M
stocks under $1 with an rsi under 10
Intellectia · 53 candidates
Price: <= $1.00Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
AIIO logo
AIIO
Robo.ai Inc
89.22M
PSTV logo
PSTV
Plus Therapeutics Inc
52.05M
HURA logo
HURA
TuHURA Biosciences Inc
41.71M
XLO logo
XLO
Xilio Therapeutics Inc
40.33M
POM logo
POM
PomDoctor Ltd
35.21M
OTLK logo
OTLK
Outlook Therapeutics Inc
32.44M

Whales Holding IINN

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Inspira Technologies Oxy BHN Ltd (IINN) stock price today?

The current price of IINN is 0.3804 USD — it has decreased -4.28

What is Inspira Technologies Oxy BHN Ltd (IINN)'s business?

Inspira Technologies Oxy B.H.N Ltd, formerly Insense Medical Ltd, incorporated on February 27, 2018, is a specialty medical device company based in Israel. The Company is engaged in the research, development, manufacture, and marketing of respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV). It provides patients with acute respiratory distress syndrome to maintain spontaneous breathing and avoid the various risks associated with the use of MV.

What is the price predicton of IINN Stock?

Wall Street analysts forecast IINN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IINN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Inspira Technologies Oxy BHN Ltd (IINN)'s revenue for the last quarter?

Inspira Technologies Oxy BHN Ltd revenue for the last quarter amounts to -3.16M USD, decreased -3.78

What is Inspira Technologies Oxy BHN Ltd (IINN)'s earnings per share (EPS) for the last quarter?

Inspira Technologies Oxy BHN Ltd. EPS for the last quarter amounts to -98.62 USD, decreased

How many employees does Inspira Technologies Oxy BHN Ltd (IINN). have?

Inspira Technologies Oxy BHN Ltd (IINN) has 38 emplpoyees as of March 31 2026.

What is Inspira Technologies Oxy BHN Ltd (IINN) market cap?

Today IINN has the market capitalization of 17.18M USD.